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Abstract
Introduction Invasive candidiasis and candidemia are life-
threatening nosocomial infections in intensive care patients.
Methods A post hoc analysis of a phase 3 trial assessing
micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for
subjects ≤ 40 kg) versus liposomal amphotericin B (3 mg/kg/
day). Subgroups were defined according to the type of ward on
the first day of treatment: intensive care unit (ICU) or non-ICU.
Multivariate regression was performed to identify factors
associated with treatment success at end of therapy and all-
cause mortality at days 8 and 30.
Results In non-ICU subjects, treatment success was
significantly higher for micafungin versus liposomal
amphotericin B (85% (n = 108/127) versus 72.1% (n = 98/
136);  P  = 0.0113). However, for ICU subjects, treatment
success rates for micafungin versus liposomal amphotericin B
were similar (62.5% (n = 75/120) versus 66.4% (n = 73/110);
P = 0.5828). Overall, treatment success was significantly lower
in ICU subjects compared with non-ICU subjects (64.3% (n =
148/230) versus 78.3% (n = 206/263); P  = 0.0006).
Multivariate regression analysis revealed a lower likelihood of
treatment success for: ICU versus non-ICU subjects; persistent
neutropenia; and high versus low Acute Physiology and Chronic
Health Evaluation (APACHE) II scores. However, when
interactions between potential explanatory factors were
included in the analysis model, ICU status no longer emerged as
a significant associated variable but the association between
APACHE II score and treatment outcome remained. Further
analyses indicated that the likelihood of mortality at day 8 and
day 30 was lower for subjects with lower APACHE II scores.
Renal function was significantly better in micafungin versus
liposomal amphotericin B subjects: a difference (liposomal
amphotericin B - micafungin in mean peak change in estimated
glomerular filtration rate (ml/minute/1.73 m2) of -18.2 (P  <
0.0001) and -17.7 (P = 0.0124) in non-ICU and ICU subjects,
respectively.
Conclusions Overall, ICU subjects had lower treatment
success rates than non-ICU subjects for both liposomal
amphotericin B and micafungin. Multivariate regression after
controlling for potential confounding factors suggested the
APACHE II score remained a potential explanatory factor
associated with treatment success, mortality at day 8, and
mortality at day 30.
Trial registration  Post hoc analysis - clinicaltrials.gov trial
NCT00106288.
APACHE: Acute Physiology and Chronic Health Evaluation; ICU: intensive care unit.Critical Care    Vol 13 No 5    Dupont et al.
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Introduction
Invasive  Candida  infections occur more often in patients
housed inside rather than outside an intensive care unit (ICU)
[1,2], with reported rates of candidemia ranging from 2 to
almost 10 per 1,000 hospital ICU admissions. This increased
incidence of invasive Candida infections in ICU patients is
important because logistic regression analyses of data from
observational studies suggest that Candida  infection is an
independent predictor of mortality among ICU patients, and
both hospitalization and length of stay in an ICU are predictors
of poor outcomes among patients with candidemia [3-8].
Candida epidemiology has changed as infections due to non-
albicans Candida species have increased [9]. This shift in the
prevalence of Candida  species is a matter of concern
because species such as Candida glabrata have been associ-
ated with reduced susceptibility to triazole antifungals [10-14].
The relatively high rate of infection by Candida spp. in ICUs,
the increasing prevalence of non-albicans Candida spp., and
the associated mortality suggest that new treatment
approaches are required. One such approach may be the
empirical use of antifungal agents that provide broad-spec-
trum coverage against Candida spp. [10,11,14-16]. Findings
from numerous prospective and retrospective studies indicate
that optimizing and reducing the delay of antifungal therapy
reduces attributable mortality in patients with candidemia
whereas inappropriate antifungal therapy is a significant pre-
dictor of mortality [3,17-20]. As a consequence of such find-
ings, the most recent update to the guidelines of the Infectious
Diseases Society of America includes a recommendation for
the use of an echinocandin for the initial management of mod-
erately severe to severe episodes of invasive candidiasis [14].
Micafungin is a novel echinocandin antifungal agent, which
has demonstrated in vitro fungicidal activity against all clini-
cally important species of Candida including those with resist-
ance to fluconazole [21-27]. In two phase 3 trials, micafungin
demonstrated non-inferiority to both caspofungin and lipo-
somal amphotericin B for the treatment of invasive candidiasis
and candidemia, and showed better tolerability compared with
liposomal amphotericin B [28,29].
We conducted a post hoc analysis of the phase 3 study com-
paring micafungin with liposomal amphotericin B to explore
the association between potential explanatory variables and
clinical outcomes in adult patients who initiated antifungal
chemotherapy in an ICU or in a non-ICU ward [29].
Materials and methods
Study objectives and design
The present study was a post hoc analysis of a double-blind,
randomized, non-inferiority study conducted by the Micafungin
Invasive Candidiasis Working Group at 115 medical centers
worldwide from January 2003 to November 2004. The primary
objective of this present analysis was to determine whether an
ICU stay was associated with the following outcomes in
patients treated for candidemia and invasive candidiasis: over-
all treatment success; mycological response; and all-cause
mortality at day 8 and day 30 post treatment initiation. The full
methodology of the study has been published previously [29].
Adult patients (age ≥ 16 years) were eligible if they had clinical
signs (that is, fever, hypothermia, hypotension, local signs and
symptoms of inflammation, radiologic evidence) of systemic
Candida infection, and had one or more positive Candida cul-
tures from blood or another sterile site within the previous 4
days.
Subjects were randomized to receive either micafungin (100
mg/day for patients > 40 kg; 2 mg/kg for patients ≤ 40 kg) or
liposomal amphotericin B (3 mg/kg per day) as first-line treat-
ment of candidemia and invasive candidiasis. During random
assignment to their respective treatment regimens, patients
were stratified by study center and neutropenia status but not
by whether or not Candida infection developed inside or out-
side an ICU.
Antifungal therapy was prescribed for a minimum treatment
period of 14 days and a maximum treatment period of 4 weeks
- except for patients with chronic disseminated candidiasis,
Candida osteomyelitis, or Candida endocarditis, for whom the
study drug could be administered for up to 8 weeks. While
patients with neutropenia who received antifungal prophylaxis
prior to the beginning of the study were eligible, non-neutro-
penic patients who had received 3 days or more of systemic
antifungal therapy within the previous week were ineligible.
The initial doses of study drugs remained fixed during the first
5 days of treatment but a dosage increase (up to 200 mg/day
for micafungin and up to 5 mg/kg/day for liposomal amphoter-
icin B) was allowed if there was mycological persistence or
ongoing clinical and radiographic evidence of infection. Con-
versely, a dose decrease of 50% for liposomal amphotericin B
was indicated for drug-related nephrotoxicity.
Clinical and mycological assessments were made at baseline
immediately prior to treatment initiation (study day 0), three
times weekly during the treatment phase, and at the end of
therapy. Assessments were continued at prespecified inter-
vals post therapy for patients who were suspected of having a
recurrent or emergent infection.
The study was approved by ethics committees of the partici-
pating centers, and all patients gave written, informed consent
for their participation.
Analysis population
The analysis populations consisted of all patients included in
the modified intent-to-treat populations, defined as all subjects
who received at least one dose of micafungin or liposomal
amphotericin B and had a confirmed Candida  infection atAvailable online http://ccforum.com/content/13/5/R159
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baseline. Subjects were retrospectively assigned to the ICU
subgroup if they stayed in the ICU for at least 1 day during
study days -1 to 3.
Analysis endpoints
The analysis endpoints were as follows: overall treatment suc-
cess, defined as success in both clinical response and myco-
logical response (success in clinical response at the end of
therapy defined as a complete or partial resolution of symp-
toms); mycological response, defined as eradication or pre-
sumed eradication of the baseline pathogen; and all-cause
mortality at day 8 and day 30 post treatment initiation. A
patient death during therapy was defined as treatment failure.
During therapy was defined as from the date of the first dose
to 1 day after the last dose.
Statistical modeling
A series of univariate analyses were performed to evaluate
associations between each treatment outcome and the ICU
status. Fisher's exact test was applied for overall treatment
success, mycological response, and all-cause mortality at day
8 and day 30. Potential explanatory variables (Table 1) were
Table 1
Exploratory variables used in the multivariate analyses
Class Study value
Treatment group Micafungin 100 mg/day
Liposomal amphotericin B 3 mg/kg/day
Age (years) Continuous
Sex Female
Male
Region Brazil, Europe, India, North America
Other
Race Caucasian
Asian-Indian
Black
Other
Primary diagnosis Candidemia
Disseminated candidiasis
Organism Candida albicans only versus non-albicans Candida
C. albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata versus other 
Candida spp.
Candida parapsilosis versus other Candida spp.
Candida krusei versus other Candida spp.
Neutropeniaa at baseline Yes/No
Persistent neutropenia Yes/No
Liver disorder/failure Yes/No
Renal disorder/failure Yes/No
Antibiotic use Yes/No
Diabetes mellitus Yes/No
Solid organ transplant Yes/No
Corticosteroid therapy Yes/No
Catheter statusb Removed within 48 hours of treatment initiation, Yes/No
Removed at any time during the study, Yes/No
Acute Physiology and Chronic Health Evaluation II score Continuous
aAbsolute neutrophil count < 500 cells/μl. bExplanatory variable used in analysis of candidemic patients only.Critical Care    Vol 13 No 5    Dupont et al.
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investigated to assess their effect on treatment outcomes.
Fisher's exact test was applied if the explanatory factor was a
discrete variable and the Wilcoxon rank sum test was used if
the explanatory factor was a continuous variable. Explanatory
variables with P ≤ 0.1 were selected as potential confounding
factors in the final multivariate models, described below as a
logistic regression model.
The effects of ICU status on overall treatment success, myco-
logical response, and all-cause mortality at day 8 and day 30
were evaluated using logistic regression analysis. The logistic
regression model used can be described as:
where p is the probability of treatment success, α is the inter-
ception, X is the vector of explanatory variables, and β is the
parameter vector to be estimated.
The ICU status and all identified potential confounding factors
were included in the model as first-order explanatory variables.
For each individual variable, the effect of the variable on treat-
ment outcome in the multivariate model was tested by the
Wald chi-square test. From the model, treatment outcome was
compared between the levels of the variable using the odds
ratio and the 95% Wald confidence interval.
Results
Baseline patient characteristics
Of the 537 adult subjects (age ≥ 16 years) enrolled and rand-
omized to receive treatment with micafungin or liposomal
amphotericin B, 494 subjects were included in the modified
intent-to-treat analysis. Subjects were evenly distributed
between the ICU (n = 263) and other hospital wards (n = 230)
at the time of treatment initiation, with one subject recorded as
ICU status unknown. The micafungin and liposomal amphoter-
icin B treatment groups were well matched with respect to the
proportion of assigned subjects in an ICU (48.6% versus
44.7%, respectively). Table 2 summarizes the baseline demo-
graphics and clinical characteristics of the analysis population,
categorized by ICU status and treatment group.
While age and sex were well matched across the subgroups,
there was a disparity in the racial composition of the ICU and
non-ICU groups in this worldwide study. The percentage of
Black subjects in the ICU group was less than that in the non-
ICU group (2.2% versus 6.8%), and the prevalence of races
other than Black or Caucasian were nearly twice as high in the
ICU group as in the non-ICU group (45.2% versus 24.3%).
There was a higher proportion of subjects from Brazil in the
non-ICU group and a higher proportion of subjects from India
in the ICU group.
With a few exceptions, the proportions of subjects with under-
lying conditions or risk factors predisposing to a nosocomial
Candida infection were similar across the ICU and non-ICU
subgroups. As expected, the mean (18.1 versus 13.8) and
median (17.5 versus 14.0) Acute Physiology and Chronic
Health Evaluation (APACHE) II scores were higher in the ICU
group than in the non-ICU group. In addition, the presence of
a central venous catheter at baseline was more frequent in the
ICU group (96.1% versus 71.8%), whereas baseline neutro-
penia was more common in non-ICU subjects (17.9% versus
4.3%). The length of hospital stay was similar across both sub-
groups.
There were no substantial differences between the micafungin
and liposomal amphotericin B treatment groups for ICU and
non-ICU subjects. Candidemia was more common than inva-
sive candidiasis in the present study, and the prevalence of
these primary diagnoses was well matched between micafun-
gin-treated and liposomal amphotericin B-treated subjects
and across the ICU and non-ICU subgroups (Table 3).
Overall and across the analysis groups, a non-albicans Cand-
ida  species was more frequently isolated at baseline than
Candida albicans. The rank order of prevalence of baseline
Candida spp. was identical across the subgroups. Although
the between-group prevalence of causative pathogens was
similar, it was noted in liposomal amphotericin B-treated sub-
jects that Candida krusei was isolated at baseline more fre-
quently in non-ICU subjects (including three patients who had
an underlying hematological disorder) compared with ICU
subjects; nine isolates versus one isolate, respectively.
Efficacy outcomes
Rates of overall treatment success, of mycological response,
and of all-cause mortality for ICU and non-ICU subjects
treated with micafungin or liposomal amphotericin B are sum-
marized in Table 4. In non-ICU subjects, the treatment success
rate was significantly higher among subjects receiving
micafungin than liposomal amphotericin B (85% versus
72.1%; P = 0.0113). For ICU subjects, however, treatment
success rates for micafungin versus liposomal amphotericin B
were similar (62.5% versus 66.4%, respectively).
Rates of mycological response were slightly higher than rates
of overall treatment success, and were consistent across both
ICU subgroups and across each treatment group. All-cause
mortality at day 8 was moderate (7.6% in non-ICU subjects
and 18.7% in ICU subjects) but increased by day 30 (21.7%
in non-ICU subjects and 36.5% in ICU subjects). Kaplan-
Meier estimates of the probability of survival in ICU and non-
ICU subjects treated with micafungin and liposomal amphoter-
icin B are displayed in Figure 1.
When the micafungin treatment group and the liposomal
amphotericin B treatment group were combined and the data
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Table 2
Baseline patient demographics and clinical characteristics of the modified full analysis set
Characteristic Micafungin Liposomal amphotericin B Total
Non-ICU (n = 127) ICU (n = 120) Non-ICU (n = 136) ICU (n = 110) Non-ICU (n = 263) ICU (n = 230)
Age (years)
Mean ± standard deviation 53.1 ± 16.90 52.4 ± 19.40 53.7 ± 18.74 53.4 ± 17.76 53.4 ± 17.85 52.9 ± 18.60
Median 54.0 54.5 55.5 56.0 55.0 56.0
Range 18.0 to 87.0 18.0 to 89.0 16.0 to 89.0 17.0 to 97.0 16.0 to 89.0 17.0 to 97.0
Male, n (%) 79 (62.2) 76 (63.3) 79 (58.1) 68 (61.8) 158 (60.1) 144 (62.6)
Female, n (%) 48 (37.8) 44 (36.7) 57 (41.9) 42 (38.2) 105 (39.9) 86 (37.4)
Race, n (%)
Black 11 (8.7) 2 (1.7) 7 (5.1) 3 (2.7) 18 (6.8) 5 (2.2)
Caucasian 84 (66.1) 65 (54.2) 97 (71.3) 56 (50.9) 181 (68.8) 121 (52.6)
Other 32 (25.20) 53 (44.17) 32 (23.5) 51 (46.4) 64 (24.3) 104 (45.2)
Region, n (%)
Brazil 37 (29.1) 18 (15.0) 42 (30.9) 15 (13.6) 79 (30.0) 33 (14.3)
Europe 37 (29.1) 46 (38.3) 43 (31.6) 34 (30.9) 80 (30.4) 80 (34.8)
India 12 (9.4) 44 (36.7) 20 (14.7) 39 (35.5) 32 (12.2) 83 (36.1)
North America 11 (8.7) 6 (5.0) 12 (8.8) 7 (6.4) 23 (8.7) 13 (5.7)
Other 30 (23.6) 6 (5.0) 19 (14.0) 15 (13.6) 49 (18.6) 21 (9.1)
APACHE II score
Mean ± standard 
deviation
13.4 ± 6.32 18.4 ± 9.39 14.1 ± 6.60 17.8 ± 9.35 13.8 ± 6.46 18.1 ± 9.35
Median 13.0 19.0 14.0 17.0 14.0 17.5
Range 0 to 30.0 0 to 44.0 0 to 37.0 0 to 47.0 0 to 37.0 0 to 47.0
Relevant risk factors
Catheter present 95 (75.4) 116 (96.7) 93 (68.4) 105 (95.5) 188 (71.8) 221 (96.1)
Bone marrow transplant 4 (3.1) 2 (1.7) 2 (1.5) 1 (0.9) 6 (2.3) 3 (1.3)
Neutropenia 26 (20.5) 6 (5.0) 21 (15.4) 4 (3.6) 47 (17.9) 10 (4.3)
Persistent neutropenia 
during therapy
11 (8.8) 3 (2.5) 7 (5.3) 2 (1.9) 18 (7.0) 5 (2.2)
Acute leukemia 20 (15.7) 1 (0.8) 13 (9.6) 3 (2.7) 33 (12.5) 4 (1.7)
Hematological disorder 37 (29.1) 7 (5.8) 24 (17.6) 8 (7.3) 61 (23.2) 15 (6.5)
Liver disorder/failure 1 (0.8) 0 (0.0) 2 (1.5) 0 (0.0) 3 (1.1) 0 (0.0)
Pancreatitis 5 (3.9) 4 (3.3) 3 (2.2) 6 (5.5) 8 (3.0) 10 (4.3)
Renal disorder/failure 0 (0.0) 2 (1.7) 1 (0.7) 0 (0.0) 1 (0.4) 2 (0.9)
Solid organ tumor 23 (18.1) 12 (10.0) 27 (19.9) 23 (20.9) 50 (19.0) 35 (15.2)
Solid organ transplant 4 (3.1) 9 (7.5) 5 (3.7) 4 (3.6) 9 (3.4) 13 (5.7)
Antibiotic use 23 (18.1) 29 (24.2) 28 (20.6) 35 (31.8) 51 (19.4) 64 (27.8)
Corticosteroid therapy 14 (11.0) 22 (18.3) 20 (14.7) 17 (15.5) 34 (12.9) 39 (17.0)
Other 
immunosuppression
9 (7.1) 11 (9.2) 8 (5.9) 7 (6.4) 17 (6.5) 18 (7.8)
Intravenous line/device 40 (31.5) 26 (21.7) 35 (25.7) 20 (18.2) 75 (28.5) 46 (20.0)
Length of hospital stay
Mean ± standard 
deviation
21.6 ± 17.77 20.0 ± 20.36 23.2 ± 20.35 27.6 ± 47.59 22.5 ± 19.13 23.6 ± 36.16
Median 18.0 14.0 19.5 15.0 19.0 14.5
Range 2 to 82.0 1 to 126.0 1 to 97.0 1 to 388.0 1 to 97.0 1 to 388.0
APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit.Critical Care    Vol 13 No 5    Dupont et al.
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analyzed only according to ICU status, the results demon-
strated that fewer ICU subjects achieved overall treatment
success than non-ICU subjects. This difference was demon-
strated to be statistically significant (64.3% versus 78.3%; P
= 0.0006).
Multivariate logistic regression analyses
Multivariate regression analyses were performed in order to
uncover the risk factors underlying the difference in treatment
success noted in ICU subjects versus non-ICU subjects.
When the logistic regression model was run without interac-
tion terms between potential confounding factors, results
revealed a lower likelihood of treatment success for ICU ver-
sus non-ICU subjects, for subjects with persistent neutropenia
during therapy, and for subjects with high versus low APACHE
II scores. In the logistic regression model including interac-
tions between ICU status and potential confounding factors
(where possible), however, the APACHE II score emerged as
the only variable associated with each of the four prespecified
outcomes analyzed (Table 5). In addition to the APACHE II
score, subjects without persistent neutropenia during therapy
were more likely to achieve overall treatment success even
when interaction terms were included in the final analysis. Sim-
ilarly, although five explanatory variables (ICU status, primary
diagnosis, neutropenia at baseline, diabetes, and APACHE II
score) were detected that may have influenced the mycologi-
cal response on initial analysis, only the APACHE II score
Table 3
Primary diagnosis and prevalence of causative Candida species
Characteristic Micafungin Liposomal amphotericin B Total
Non-ICU (n = 127) ICU (n = 120) Non-ICU (n = 136) ICU (n = 110) Non-ICU (n = 263) ICU (n = 230)
Primary diagnosis
Candidemia 109 (85.8) 98 (81.7) 115 (84.6) 94 (85.5) 224 (85.2) 192 (83.5)
Invasive candidiasis 18 (14.2) 22 (18.3) 21 (15.4) 16 (14.5) 39 (14.8) 38 (16.5)
Isolated Candida spp. at baselinea
Candida albicans 44 (34.6) 58 (48.3) 55 (40.4) 54 (49.1) 99 (37.6) 112 (48.7)
Candida parapsilosis 29 (22.8) 13 (10.8) 22 (16.2) 16 (14.5) 51 (19.4) 29 (12.6)
Candida tropicalis 37 (29.1) 29 (24.2) 36 (26.5) 26 (23.6) 73 (27.8) 55 (23.9)
Candida glabrata 15 (11.8) 15 (12.5) 10 (7.4) 9 (8.2) 25 (9.5) 24 (10.4)
Candida krusei 5 (3.9) 4 (3.3) 9 (6.6) 1 (0.9) 14 (5.3) 5 (2.2)
Other Candida species 6 (4.7) 11 (9.2) 17 (12.5) 14 (12.7) 23 (8.7) 25 (10.9)
Data presented as n (%). ICU, intensive care unit. aA patient may have had more than one Candida spp. isolated at baseline.
Table 4
Treatment response, mycological response, and crude mortality rates
Outcome Micafungin Liposomal amphotericin B P valuea Total
Non-ICU 
(n = 127)
ICU 
(n = 120)
Non-ICU 
(n = 136)
ICU 
(n = 110)
Non-ICU ICU Non-ICU 
(n = 263)
ICU 
(n = 230)
P value
Overall 
treatment 
success
108 (85.0) 75 (62.5) 98 (72.1) 73 (66.4) 0.0113* 0.5828 206 (78.3) 148 (64.3) 0.0006*
Mycological 
response
109 (85.8) 88 (73.3) 106 (77.9) 79 (71.8) 0.1115 0.8825 215 (81.7) 167 (72.6) 0.2371
All-cause 
mortality at day 
8
6 (4.7) 25 (20.8) 14 (10.3) 18 (16.4) 0.1057 0.4028 20 (7.6) 43 (18.7) 0.8935
All-cause 
mortality at day 
30
25 (19.7) 46 (38.3) 32 (23.5) 38 (34.5) 0.4589 0.5852 57 (21.7) 84 (36.5) 0.0003*
Data presented as n (%). ICU, intensive care unit. aMicafungin versus liposomal amphotericin B. *Statistically significant.Available online http://ccforum.com/content/13/5/R159
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emerged as a statistically significant explanatory variable asso-
ciated with mycological response in the final analysis.
Potential explanatory factors demonstrating an association
with an increased likelihood of mortality at day 8 were C. kru-
sei  versus other Candida  species and a high versus low
APACHE II score. Increasing age, persistent neutropenia, and
APACHE II score were associated with a higher likelihood of
mortality at day 30. These associations remained statistically
significant when interaction terms were included in the final
model.
Safety
Renal function was significantly better in subjects who
received micafungin than those who received liposomal
amphotericin B. The difference (liposomal amphotericin B
group - micafungin group) in the mean peak change in the esti-
mated glomerular filtration rate was -18.2 ml/minute/1.73 m2
(P < 0.0001) and -17.7 ml/minute/1.73 m2 (P = 0.0124) in
non-ICU subjects and in ICU subjects, respectively.
Discussion
Given that many ICU patients will become infected by one or
more Candida spp. at some point during hospitalization [30],
it is important that ongoing research is conducted to identify
those risk factors that are most likely to influence health out-
comes in this multimorbid, heterogeneous patient population.
In this post hoc subgroup analysis of a prospective, rand-
omized clinical trial - conducted in line with various recommen-
dations for post hoc analysis [31-35] - the rate of overall
treatment success was higher in non-ICU patients receiving
micafungin than those receiving liposomal amphotericin B. In
ICU patients, overall treatment success rates in patients who
received micafungin or liposomal amphotericin B were similar,
and were lower than the corresponding treatment success
rates in non-ICU patients.
Although ICU patients had lower treatment success rates than
non-ICU patients, multivariate regression analysis revealed
that the ICU status was not associated with treatment out-
come when potential confounding factors were considered.
The APACHE II score was the only potential explanatory vari-
able associated with treatment success, mortality at day 8, and
mortality at day 30. Catheter status had no effect on any out-
come in patients with candidemia (data not shown).
These results seem to be at odds with post hoc observations
from a prospective randomized study assessing the safety and
efficacy of caspofungin versus amphotericin B deoxycholate in
patients with invasive candidiasis [36,37]. Multivariate regres-
sion analysis indicated that patients initiating antifungal treat-
ment in an ICU were more likely to die than those initiating
antifungal therapy outside an ICU even after accounting for
APACHE II score [36]. It should be noted, however, that a
study of caspofungin versus amphotericin B deoxycholate
treatment measured all-cause mortality 6 to 8 weeks after
completion of study therapy [36] whereas the analysis we
describe here measured all-cause mortality 30 days post treat-
ment initiation.
Figure 1
Probability of survival in subjects treated with micafungin and liposomal amphotericin B Probability of survival in subjects treated with micafungin and liposomal amphotericin B. Kaplan--Meier estimates of survival in intensive care unit 
(ICU) subjects and non-ICU subjects.Critical Care    Vol 13 No 5    Dupont et al.
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The all-cause mortality rate at day 30 in our analysis was in
general agreement with data derived from observational stud-
ies [4,38-51]. Using multivariate analyses, findings from obser-
vational studies [4,17,39,42] and a prospective clinical trial
[52] have underscored the importance of the APACHE II
score as a prognostic indicator. In one of the observational
studies, graded APACHE II scores were not only strongly
associated with 3-month mortality but a linear relationship also
existed between these variables for most Candida spp. [39].
Furthermore, analysis of prospective, randomized, controlled
trial data clearly demonstrated that the risk of failing study ther-
apy increased incrementally with APACHE II score (odds ratio
= 1.09 per points, 95% confidence interval = 1.03 to 1.14; P
= 0.001) [52].
Conclusions
While it is important to realize the limitations inherent in any
post hoc analysis, the analysis described here remains one of
the most extensive such investigations of the associations
between the stay in an ICU and clinical outcomes in patients
with confirmed candidemia or invasive candidiasis. Our find-
ings underscore the importance of the APACHE II score as a
prognostic indicator in both ICU patients and non-ICU
patients with invasive Candida infections.
Table 5
Significant predictors of overall treatment success, mycological response and mortality
Variable Ratio Without interaction 
termsa
With interaction terms
Maximum likelihood 
estimate 
(± standard error)
Wald χ2 (probability > χ2)
Overall treatment success
ICU statusb Not in ICU to in ICU 1.866 (1.147 to 3.034) 0.1380 ± 0.5438 0.0644 (0.7997)
Persistent neutropenia Non-neutropenic to 
neutropenic
5.721 (1.412 to 23.169) 1.7185 ± 0.7156 5.7669 (0.0163)
APACHE II score High to low (continuous) 0.956 (0.929 to 0.983) --0.0468 ± 0.0144 10.6416 (0.011)
Mycological response
ICU statusb Not in ICU to in ICU 1.778 (1.037 to 3.048) --0.0223 ± 1.7567 0.0002 (0.9899)
Primary diagnosis Candidemia to invasive 
candidiasis
2.465 (1.343 to 4.524) 0.3246 ± 0.4368 0.5522 (0.4574)
Neutropeniab Non-neutropenic to 
neutropenic
2.357 (1.134 to 4.898) --0.9093 ± 1.0206 3.4859 (0.0619)
Diabetes mellitus No to yes 0.350 (0.137 to 0.894) --1.0113 ± 0.5362 3.5572 (0.0593)
APACHE II score High to low (continuous) 0.953 (0.925 to 0.982) --0.0505 ± 0.0154 10.7417 (0.001)
All-cause mortality at day 8
Candida spp. Candida krusei to other 
Candida spp.
3.536 (1.039 to 12.035) 2.4861 ± 1.3739 3.2745 (0.0704)
APACHE II score High to low (continuous) 1.097 (1.055 to 1.142) 0.0931 ± 0.0208 20.0498 (< 0.0001)
All-cause mortality at day 
30
Age Low to high 1.018 (1.003 to 1.033) 0.0170 ± 0.0076 4.9331 (0.0263)
Persistent neutropenia Non-neutropenic to 
neutropenic
0.160 (0.039 to 0.658) --1.7845 ± 0.7146 6.2358 (0.0125)
APACHE II score High to low (continuous) 1.093 (1.057 to 1.131) 0.0937 ± 0.0178 27.7797 (< 0.0001)
Significant predictors of overall treatment success, mycological response and mortality based on a logistic regression model that controlled for 
potential confounding variables with and without interaction terms. APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care 
unit. aOdds ratio (95% confidence interval). bAt the time of treatment initiation.Available online http://ccforum.com/content/13/5/R159
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